Polyrizon Expands U.S. Patent Claims for Intranasal Hydrogel to Cover Drug Delivery Methods
Polyrizon submitted amended claims to its U.S. patent application extending protection to drug delivery systems and methods covering sulfated polysaccharide hydrogel compositions that form films on mucosal surfaces. The expanded claims aim to enhance drug residence time, improve API bioavailability and support controlled film formation compatible with diverse therapeutic agents.
1. Expanded U.S. Patent Claims
Polyrizon submitted amended claims to its U.S. patent application broadening scope from mucoadhesive hydrogel composition to include drug delivery systems and specific methods of use, particularly for sulfated polysaccharide polymer compositions forming continuous mucosal films.
2. Key Technological Features
The platform’s features include prolonged drug residence time at administration sites, improved API bioavailability through enhanced mucosal interaction, controlled film formation upon contact with epithelial tissues and compatibility with diverse therapeutic agents.
3. Strategic and Commercial Implications
By extending patent protection to delivery systems and methods, Polyrizon bolsters its intellectual property portfolio, potentially increasing platform value and opening opportunities across multiple therapeutic areas as it advances toward commercialization.